Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines

Genes Chromosomes and Cancer

Volumn 41, Issue 1, 2004, Pages 65-79

  Williams, Richard D ^a   Hing, Sandra N ^a   Greer, Braden T ^b   Whiteford, Craig C ^b   Wei, Jun S ^b   Natrajan, Rachael ^a   Kelsey, Anna ^c   Rogers, Simon ^d   Campbell, Colin ^d   Pritchard Jones, Kathy ^a   Khan, Javed ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CHROMOSOME 1Q; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MARKER GENE; NEPHRECTOMY; NEPHROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INFANT; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECURRENCE; WILMS TUMOR;

EID: 3342939836     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20060     Document Type: Article

References (53)

1. Arcellana-Panlilio MY, Egeler RM, Ujack E, Pinto A, Demetrick DJ, Robbins SM, Coppes MJ. 2000. Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in Wilms tumor. Genes Chromosomes Cancer 29:63-69.
2. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J. 1994. Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7:91-97.
3. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824.
4. Bengtsson H. 2002. com.braju.sma-Object-oriented microarray analysis in 100% R. (http://www.maths.lth.se/help/R/com.braju.sma/HBengtsson-com.braju.sma. pdf).
5. Camassei FD, Jenkner A, Rava L, Bosman C, Francalanci P, Donfrancesco A, Alo PL, Boldrini R. 2003. Expression of the lipogenic enzyme fatty acid synthase (FAS) as a predictor of poor outcome in nephroblastoma: An interinstitutional study. Med Pediatr Oncol 40:302-308.
6. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L. 2001. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2:269-274.
7. Chen Y, Kamat V, Dougherty ER, Bittner ML, Meltzer PS, Trent JM. 2002. Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics 18:1207-1215.
8. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826.
9. Dome JS, Coppes MJ. 2002. Recent advances in Wilms tumor genetics. Curr Opin Pediatr 14:5-11.
10. Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey LA, Grundy PE, Perlman EJ, Breslow NE, Sukumar S. 1999. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res 59:4301-4307.
11. Donovan MJ, Hempstead B, Huber LJ, Kaplan D, Tsoulfas P, Chao M, Parada L, Schofield D. 1994. Identification of the neurotrophin receptors p75 and trk in a series of Wilms' tumors. Am J Pathol 145:792-801.
12. Dudoit S, Fridlyand J. 2003. Classification in microarray experiments. In: Speed T, editor. Statistical analysis of gene expression microarray data. Boca Raton: Chapman and Hall/CRC. p 115.
13. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF. 2003. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33:90-96.
14. Efferth T, Schulten HG, Thelen P, Bode ME, Beniers AJ, Granzen B, Ringert RH, Mertens R, Gefeller O, Jakse G, Fuzesi L. 2001a. Differential expression of the heat shock protein 70 in the histological compartments of nephroblastomas. Anticancer Res 21:2915-20.
15. Efferth T, Thelen P, Schulten HG, Bode ME, Granzen B, Beniers AJ, Mertens R, Ringert RH, Gefeller O, Jakse G, Fuzesi L. 2001b. Differential expression of the multidrug resistance-related protein MRP1 in the histological compartments of nephroblastomas. Int J Oncol 19:367-371.
16. Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, Brodeur GM, Evans AE. 2001. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 19:689-696.
17. Franzon VL, Gibson MA, Hatzinikolas G, Woollatt E, Sutherland GR, Cleary EG. 1999. Molecular cloning of a novel human PAPS synthetase which is differentially expressed in metastatic and non-metastatic colon carcinoma cells. Int J Biochem Cell Biol 31:613-626.
18. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. 2000. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 16:906-914.
19. Ghanem MA, Van der Kwast TH, Den Hollander JC, Sudaryo MK, Oomen MH, Noordzij MA, Van den Heuvel MM, Nassef SM, Nijman RM, Van Steenbrugge GJ. 2000. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma. Clin Cancer Res 6:4265-4271.
20. Ghanem MA, Van Der Kwast TH, Den Hollander JC, Sudaryo MK, Mathoera RB, Van den Heuvel MM, Noordzij MA, Nijman RJ, van Steenbrugge GJ. 2001a. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer 92:3120-3129.
21. Ghanem MA, Van der Kwast TH, Den Hollander JC, Sudaryo MK, Van den Heuvel MM, Noordzij MA, Nijman RJ, Soliman EH, van Steenbrugge GJ. 2001b. The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. Br J Cancer 85:1557-1563.
22. Ghanem MA, Van Steenbrugge GJ, Van Der Kwast TH, Sudaryo MK, Noordzij MA, Nijman RJ. 2002. Expression and prognostic value of CD44 isoforms in nephroblastoma (Wilms tumor). J Urol 168:681-686.
23. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, Mathoera RB, Nijman JM, van der Kwast TH. 2003. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 56:107-113.
24. Hastie T, Tibshirani R, Friedman JH. 2001. The elements of statistical learning. Basel: Springer Verlag. p 193-224.
25. Hegde P, Qi R, Abernathy K, Gay C, Dharap S, Gaspard R, Hughes JE, Snesrud E, Lee N, Quackenbush J. 2000. A concise guide to cDNA microarray analysis. Biotechniques 29:548-50, 552-554, 556 passim.
26. Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholson J, Grundy P, Grundy R, Gessler M, Shipley J, Pritchard-Jones K. 2001. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 158:393-398.
27. Kent WJ. 2002. BLAT-the BLAST-like alignment tool. Genome Res 12:656-664.
28. Khan J, Wei JS, Ringner M Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS. 2001. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7:673-679.
29. Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R, Klein U, Tycko B. 2002. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160:2181-2190.
30. Lu YJ, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K. 2002. Chromosome 1q expression profiling and relapse in Wilms' tumor. Lancet 360:385-386.
31. Nisen PD, Zimmerman KA, Cotter SV, Gilbert F, Alt FW. 1986. Enhanced expression of the N-myc gene in Wilms' tumors. Cancer Res 46:6217-6222.
32. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. 2002. Prediction of central nervous system embryonal tumor outcome based on gene expression. Nature 415:436-442.
33. Pritchard-Jones K, Fleming S. 1991. Cell types expressing the Wilms' tumor gene (WT1) in Wilms' tumors: implications for tumor histogenesis. Oncogene 6:2211-20.
34. Re GG, Willingham MC, el Bahtimi R, Brownlee NA, Hazen-Martin DJ, Garvin AJ. 1997. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor. Mod Pathol 10:129-136.
35. Reeve AE, Eccles MR, Wilkins RJ, Bell GI, Millow LJ. 1985. Expression of insulin-like growth factor-II transcripts in Wilms' tumor. Nature 317:258-260.
36. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J. 2003. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34:374-378.
37. Saikali Z, Sinnett D. 2000. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 89:418-422.
38. Sakamoto K, Yamaguchi S, Ando R, Miyawaki A, Kabasawa Y, Takagi M, Li CL, Perbal B, Katsube K. 2002. The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notchl extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J Biol Chem 277:29399-405.
39. Schuler GD, Boguski MS, Stewart EA, Stein LD, Gyapay G, Rice K, White RE, Rodriguez-Tome P, Aggarwal A, Bajorek E, Bentolila S, Birren BB, Butler A, Castle AB, Chiannilkulchai N, Chu A, Clee C, Cowles S, Day PJ, Dibling T, Drouot N, Dunham I, Duprat S, East C, Hudson TJ, et al. 1996. A gene map of the human genome. Science 274:540-546.
40. Schulz S, Becker KF, Braungart E, Reichmuth C, Klamt B, Becker I, Atkinson M, Gessler M, Hofler H. 2000. Molecular analysis of E-cadherin and cadherin-II in Wilms' tumors. J Pathol 191:162-169.
41. Scott J, Cowell J, Robertson ME, Priestley LM, Wadey R, Hopkins B, Pritchard J, Bell GI, Rall LB, Graham CF, et al. 1985. Insulin-like growth factor-II gene expression in Wilms' tumor and embryonic tissues. Nature 317:260-262.
42. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. 2002. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1:203-209.
43. Skotnicka-Klonowicz G, Kobos J, Los E, Trejster E, Szymik-Kantorowicz S, Daszkiewicz P. 2002. Prognostic value of proliferating cell nuclear antigen in Wilms' tumor in children. Eur J Surg Oncol 28:67-71.
44. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Macese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
45. Sredni ST, de Camargo B, Lopes LF, Teixeira R, Simpson A. 2001. Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor. Med Pediatr Oncol 37:455-458.
46. Sturn A, Quackenbush J, Trajanoski Z. 2002. Genesis: cluster analysis of microarray data. Bioinformatics 18:207-208.
47. Takahashi M, Yang XJ, Lavery TT, Furge KA, Williams BO, Tretiakova M, Montag A, Vogelzang NJ, Re GG, Garvin AJ, Soderhall S, Kagawa S, Hazel-Martin D, Nordenskjold A, Teh BT. 2002. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res 62:6598-6605.
48. Toretsky JA, Zitomersky NL, Eskenazi AE, Voigt RW, Strauch ED, Sun CC, Huber R, Meltzer SJ, Schlessinger D. 2001. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 23:496-499.
49. Udtha M, Lee SJ, Alam R, Coombes K, Huff V. 2003. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors. Oncogene 22:3821-3826.
50. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009.
51. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
52. Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-Jones K, Shipley J. 1996. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 56:3220-3224.
53. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Jr., Marks JR, Nevins JR. 2001. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98:11462-11467.